Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Nurix Therapeutics, Inc.’s 10-Q, filed July 9, 2026.
- Filed
- Jul 9, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001549595-26-000040
| Line item | Three Months Ended May 31, 2026 | Three Months Ended May 31, 2025 | Six Months Ended May 31, 2026 | Six Months Ended May 31, 2025 |
|---|---|---|---|---|
| Total revenue | 9,043 | 44,056 | 15,295 | 62,509 |
| Operating expenses: | ||||
| Research and development | 87,653 | 78,096 | 171,789 | 147,759 |
| General and administrative | 15,594 | 14,282 | 30,205 | 25,936 |
| Total operating expenses | 103,247 | 92,378 | 201,994 | 173,695 |
| Loss from operations | (94,204) | (48,322) | (186,699) | (111,186) |
| Interest and other income, net | 4,398 | 5,618 | 9,719 | 12,131 |
| Loss before income taxes | (89,806) | (42,704) | (176,980) | (99,055) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Nurix Therapeutics, Inc.'s G&A?
- Nurix Therapeutics, Inc. (NRIX) reported G&A of $15.59M in Q1 2026.
- How has Nurix Therapeutics, Inc.'s G&A changed year-over-year?
- Nurix Therapeutics, Inc.'s G&A increased by 9.2% year-over-year, from $14.28M to $15.59M.
- What is the long-term trend for Nurix Therapeutics, Inc.'s G&A?
- Over 4 years (2021 to 2025), Nurix Therapeutics, Inc.'s G&A has grown at a 14.0% compound annual growth rate (CAGR), from $31.2M to $52.74M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Nurix Therapeutics, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude